Personalizing cancer treatment based on the genetic map of the individual is on the cutting edge of medicine. But some oncologists may be jumping the gun, according to a clinical trial published in Lancet Oncology. They’re prescribing these personalized—and expensive—cancer drugs for patients even when they haven’t been studied for those particular cancers. It’s called off-label use. But the results are no better than with conventional chemotherapy.